


Algorithm for Endocrine Treatment and Targeted Therapy for HR-Positive, HER2-Negative Metastatic Breast Cancer



Notes.
¹If patient is premenopausal, initiate ovarian suppression, and continue as postmenopausal.
²Patients receiving alpelisib should have laboratory and symptom monitoring weekly for the first four weeks of therapy in order to avoid serious toxicity.

Abbreviations.
 CDK, cyclin-dependent kinase; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; PARP, poly-ADP-ribose polymerase

This algorithm is derived from recommendations in Endocrine Treatment and Targeted Therapy for Hormone–Receptor Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer: ASCO Guideline Update and Testing for ESR1 Mutations to Guide Therapy for HR-Positive, HER2-Negative Metastatic Breast Cancer: ASCO Guideline Rapid Recommendation Update. This is a tool based on an ASCO Guideline and is not intended to substitute for the independent professional judgment of the treating physician. Practice guidelines do not account for individual variation among patients. This tool does not purport to suggest any particular course of medical treatment. Use of the guideline and this tool are voluntary.